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Anandamidea b s t r a c t
Fatty acid amide hydrolase (FAAH), the enzyme responsible for terminating signaling by the endocannab-
inoid anandamide, plays an important role in the endocannabinoid system, and FAAH inhibitors are
attractive drugs for pain, addiction, and neurological disorders. The synthesis, radiosynthesis, and evalu-
ation, in vitro and ex vivo in rat, of an 18F-radiotracer designed to image FAAH using positron emission
tomography (PET) is described.
Fluorine-18 labelled 3-(4,5-dihydrooxazol-2-yl)phenyl (5-ﬂuoropentyl)carbamate, [18F]5, was synthe-
sized at high speciﬁc activity in a one-pot three step reaction using a commercial module with a radio-
chemical yield of 17–22% (from [18F]ﬂuoride). In vitro assay using rat brain homogenates showed that 5
inhibited FAAH in a time-dependent manner, with an IC50 value of 0.82 nM after a preincubation of
60 min. Ex vivo biodistribution studies and ex vivo autoradiography in rat brain demonstrated that
[18F]5 had high brain penetration with standard uptake values of up to 4.6 and had a regional distribution
which correlated with reported regional FAAH enzyme activity. Speciﬁcity of binding to FAAH with [18F]5
was high (>90%) as demonstrated by pharmacological challenges with potent and selective FAAH inhib-
itors and was irreversible as demonstrated by radioactivity measurements on homogenized brain tissue
extracts.
We infer from these results that [18F]5 is a highly promising candidate radiotracer with which to image
FAAH in human subjects using PET and clinical studies are proceeding.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction hydrocannabinol (THC) as the active psychotropic component of
3The identiﬁcation1 and cloning2 of the cannabinoid 1 (CB1)
receptor took some time following the discovery of delta-9-tetra-Cannabis sativa. However, subsequent elucidations in the endo-
cannabinoid system have been much more rapid4–7 and the endo-
cannabinoid system has emerged as an important target for basic
neuroscience studies, as well as providing targets for therapeutic
drugs.5,7–12
One of the problems associated with cannabinoids as therapeu-
tic agents is their propensity to cause central psychotropic effects,
and a proposed way around this has been the targeting of the en-
zymes regulating endocannabinoid levels. The enzyme fatty acid
amide hydrolase (FAAH), which regulates the levels of the endog-
enous signaling molecule anandamide (AEA) may be useful in this
respect.13 Unlike ‘classical’ hydrophilic neurotransmitters lipo-
philic AEA is not stored in vesicles but rather is produced on
demand and is rapidly degraded by FAAH to terminate signal-
ing.14,15 FAAH is found in many tissues, in particular the brain, li-
ver, and kidney, and within the brain the activity varies across
Scheme 2. Radiosynthesis of [18F]5.
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and cortex, and the lowest in the brain stem.14,16 Selective inhibi-
tors of FAAH have been actively pursued as a method to increase
AEA levels and activate CB1 receptors in a focused manner, with
the aim of providing therapeutic effects in a variety of disorders
including pain, addiction, and obesity.10,12,16–24 Such compounds
do not produce the ‘cannabis-like’ behaviors seen with CB1 recep-
tor agonists.17,18
In vivo imaging of the endocannabinoid system has also been
pursued using positron emission tomography (PET) and a variety
of radiotracers for the CB1 receptor have been successfully devel-
oped and translated into human PET studies.19–23 For FAAH, a num-
ber of positron emitting radiotracers have been reported by us and
others,24–28 but only one has been validated for use in imaging FAAH
in humans, namely [11C]CURB.29While this radiotracer showsmuch
promise, it is labelled with the short-lived radionuclide 11C (t1/
2 = 20.4 min) and thus its use is conﬁned to sites that have an on-site
cyclotron for the production of 11C. Fluorine-18 is the other com-
monly used radionuclide in PET and, with a half-live of 109.8 min,
can be shipped and used at remote locations, thereby enablingmul-
ti-center trials.30We describe here the synthesis and radiosynthesis
of a novel and potent FAAH inhibitor, 3-(4,5-dihydrooxazol-2-yl)-
phenyl (5-ﬂuoropentyl)carbamate, 5, radiolabelled at high speciﬁc
activity with 18F. Evaluation in vitro and ex vivo in rats shows that
[18F]5 is a potent FAAH inhibitor with excellent brain penetration,
appropriate regional distribution, andhigh speciﬁc binding to FAAH.
2. Results
2.1. Chemistry
Compound 5 was synthesised in four steps from 5-amino-1-
pentanol (Scheme 1). Protection of the amino group of the amino
alcohol was effected with t-Boc anhydride to form 1, followed by
ﬂuorination with DAST, yielding 3. Acid catalysed removal of the
t-Boc group of 3 gave 5-ﬂuoropentylamine 4 as the hydrochloride
salt. Coupling of this ﬂuoroamine with the p-nitrophenylcarbonate
of 3-(4,5-dihydrooxazol-2-yl)phenol, 6, provided 5 in an overall
yield of 14% (four steps). The t-Boc protected tosylate of 5-ami-
no-1-pentanol, 2, which was required for radiolableling, was syn-
thesised from 1 using p-toluenesulphonyl chloride in
dichloromethane while the activated carbonate, 6, was obtained
by acylation of 3-(4,5-dihydrooxazol-2-yl)phenol with p-nitrophe-
nylchloroformate in DMSO.
2.2. Radiochemistry
The radiosynthesis of [18F]5 is outlined in Scheme 2. Displace-
ment of the tosyl group of 2 by [18F]ﬂuoride proceeded smoothlyScheme 1. Synthesis of 5 and precursors required for radiosynthesis of [18F]5 and the ac
TsCl, TEA, 82%; (c) DAST, DCM, 43%; (d) HCl in MeOH, 94%; (e) compound 6, KHCO3, 39at 80 C in acetonitrile to give the t-Boc protected [18F]-ﬂuoropen-
tylamine with incorporation yields of 70–80%. Removal of the t-Boc
group was effected by addition of dilute sulfuric acid with 85–95%
efﬁciency, yielding [18F]4. After neutralising the acid with phos-
phate buffer, [18F]4 was coupled with carbonate 6 at 80 C to gen-
erate [18F]5 in 70–80% radiochemical yield.
Reverse-phase HPLC puriﬁcation (see SI, Fig. S1), followed by so-
lid-phase formulation and sterile ﬁltration, gave [18F]5 suitable for
animal studies in an isolated uncorrected radiochemical yield (from
[18F]ﬂuoride) of 17–22% (n = 7). The synthesis took 52–55 min from
end-of-bombardment while the radiochemical purity was >97%
with speciﬁc activities of 74–144 GBq/lmol at end-of-synthesis.
2.3. Inhibition of FAAH by compound 5
The ability of 5 to inhibit FAAH activity was measured using rat
brain homogenates and [3H]anandamide as substrate50 (Fig. 1).
Following a 60 min preincubation phase, the compound inhibited
FAAH with a pI50 value of 9.09 ± 0.04, corresponding to an IC50 va-
lue of 0.82 nM (Fig. 1A). Its inhibitory potency was dependent upon
the pre-incubation time used, a characteristic of irreversible en-
zyme inhibitors (Fig. 1B).
2.4. Biodistribution of [18F]5 in rat brain
Upon tail vein injection of high speciﬁc activity [18F]5 (<1 nmol/
kg) into conscious rats, brain uptake of radioactivity was rapid and
high asmeasured by ex vivo dissection and counting of radioactivity
in speciﬁc brain regions (Fig. 2). Based on previous studies, the cal-
culated occupancy of the enzyme is less than 2% at these mass
doses.{Wilson, 2011 #4101} At 2 min post-injection radioactivity
in cortex (a FAAH rich region)16 was 3.9 ± 0.70 SUV, which increased
modestly to 4.55 ± 0.57 SUV at 40 min post-injection. The hypothal-
amus (a comparatively FAAH-poor region)had radioactivity levels of
1.74 ± 0.18 SUV and 1.59 ± 0.24 SUV at 2 and 40 min post-injection,
respectively. To demonstrate that radiotracer uptake was mediatedtivated carbonate, 6. Reagents and conditions: (a) t-Boc anhydride, K2CO3, 74%; (b)
%.
Figure 1. Inhibition of rat brain FAAH-catalysed [3H]anandamide hydrolysis by compound 5. Panel A shows a concentration–response curve using a preincubation time of
60 min, and Panel B shows the inhibition produced by three concentrations of 5 following different preincubation times. Given that the incubation time was 10 min, the
inhibition seen at preincubation time zero is likely to have a time-dependent component. Data are means ± SEM, n = 3.
Figure 2. Biodistribution of [18F]5 in rat brain at 2 and 40 min post tail vein
injection (n = 4/group, mean ± SD). The blocked groups received URB597 (2 mg/kg,
ip) or PF-04457845 (0.5 mg/kg, ip) 30 min before radiotracer. ⁄p <0.05.
Figure 3. Amount of radioactivity irreversibly bound to rat brain tissue at 2, 10, and
40 min post tail vein injection of [18F]5 (n = 4–6/group, mean ± SD). The blocked
group received URB597 (2 mg/kg, ip) 30 min before radiotracer. ⁄p <0.05.
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totypical carbamate FAAH inhibitor URB597 (2 mg/kg, ip) or the re-
cently developed urea FAAH inhibitor, PF-04457845 (0.5 mg/kg, ip),
30 min prior to radiotracer administration.31–35 Both inhibitors
emphatically reduced uptake of radioactivity in all brain regions be-
tween 90% (hypothalamus) and 96% (cortex)with >90% reduction in
uptake in the whole brain compared with controls (Fig. 2). Radioac-
tivity levels in plasmawere signiﬁcantly elevated in pre-treated ani-
mals, an effect seen previously for FAAH radiotracers.27,36
2.5. Irreversible binding of [18F]5 to rat brain parenchyma
Upon injection of [18F]5 to groups of conscious rats, whole
brains were excised, homogenized, and exhaustively extracted
with aqueous acetonitrile to differentiate irreversibly bound radio-
tracer from unbound.37 Following centrifugation, radioactivities in
the washed pellet (bound) and in the combined supernatant (un-
bound) were counted (Fig. 3). Even at 2 min post-injection, most
(91%) of the radioactivity was irreversibly bound to brain paren-
chyma, an amount which did not change signiﬁcantly at 10 min
(94%) or 40 min (90%) post-injection, although the absolute
amount of radioactivity bound did increase over this time period.
Pretreatment of rats with URB597 (2 mg/kg, ip) 30 min prior to
radiotracer injection reduced the amount of radioactivity irrevers-ible bound by >98% compared with the control group and only 24%
of total brain radioactivity was bound to tissue.
2.6. Metabolism of [18F]5
Reverse-phase radio-HPLC analysis of rat plasma 10 min post-
radiotracer injection showed that almost complete (>95%) metab-
olism had occurred, with the radioactivity associated with hydro-
philic metabolites. However this analysis was compromised as
we found the radiotracer to be unstable in rat plasma. Incubation
of [18F]5 in vitro in rat plasma at ambient temperature resulted
in >50% decomposition within 30 min (Fig. 4). In contrast, [18F]5
was stable in human plasma during the same time-period, with
<5% decomposition, perhaps suggesting that decomposition
in vitro in rat plasma was mediated by carboxylesterases as these
enzymes are not present in human plasma.35,38
Radio-HPLC analysis of rat brain extracts, 10 min post-radio-
tracer injection showed that 50% of the extractable radioactivity
was metabolized [18F]5 (data not shown). However it must be
noted that extractable radioactivity represents <10% of the total
radioactivity present in the brain (vide supra). In addition, as
brains were non-perfused, the vasculature compartment of the
rat brain (5%) represents a signiﬁcant source of extractable radio-
activity under these conditions.
Figure 4. Radio-HPLC chromatograms of [18F]5 upon incubation in rat and human
plasma for 30 min at ambient temperature.
4354 O. Sadovski et al. / Bioorg. Med. Chem. 21 (2013) 4351–43572.7. Ex vivo autoradiography of [18F]5 in rat brain
Figure 5 shows autoradiographic images of [18F]5 at the level of
the forebrain (A) and cerebellum (B). As illustrated, considerable
labelling was present in cortex, hippocampus, thalamic and amyg-
daloid nuclei (A) as well as cerebellar cortex (B). Signal was also
clearly seen in the ventricular space, which is consistent with pre-
viously reports of expression of FAAH in the choroid plexus.39–41
Pretreatment with 0.5 mg/kg of PF-04457845 (C and D) completely
abolished binding in all brain regions, indicating exceptional spec-
iﬁcity of the radiotracer for its target sites ex vivo.
3. Discussion
Our target compound, 3-(4,5-dihydrooxazol-2-yl)phenyl (5-ﬂu-
oropentyl)carbamate, 5, (log D, pH 7.4 of 2.33) was chosen on the
basis of previous preclinical studies with 11C-labelled FAAH inhib-
itors which showed that N-alkyl-3-(4,5-dihydrooxazol-2-yl)phenyl
carbamates possess excellent properties as FAAH imaging radiotra-
cers, including high brain uptake, selectivity, and fast kinetics.28 In
vitro enzyme assays showed that 5 was also a potent and irrevers-
ible inhibitor of FAAH with an IC50 of 0.8 nM, akin to its non-ﬂuo-
rinated analogues.28 While one-step radiolabelling is always
desirable, especially when dealing with short-lived radioisotopes,
direct introduction of 18F into 5 using arylsulphonate esters as pre-
cursors proved unfruitful. Under the basic conditions required forFigure 5. Ex vivo autoradiography of [18F]5 in rat brain; control (A and B) and
blocked (C and D). See Figure S2 for more slices.18F-nucleophilic substitution reactions, such aryl carbamates un-
dergo a facile and rapid E2 elimination reaction which precluded
introduction of [18F]ﬂuoride directly.42 However, judicious choice
of reaction conditions that efﬁciently generated a synthetically
versatile [18F]ﬂuoroamine, [18F]4, allowed [18F]5 to be prepared
in an efﬁcient one-pot three-step reaction (Scheme 1), which was
easily automated using a commercial apparatus.
The suitability of [18F]5 as a radiotracer for imaging FAAH by
PET was demonstrated in several ways:
(1) Ex vivo biodistribution studies showed that brain penetra-
tion of [18F]5 was high and mediated by FAAH as pre-treat-
ment with established and selective FAAH inhibitors
URB597 or PF-04457845 blocked >90% of brain uptake
(Fig. 2).
(2) The brain regional uptake of radioactivity 40 min post
administration of [18F]5 correlated well with the reported
regional FAAH enzyme activity in rat brain. A similar corre-
lation was found with the clinically used 11C-radiotracer
[11C]CURB and related analogs,26 as well as the closely
related congener of 5, [11C]8 reported elsewhere (Fig. 6).28
This is direct evidence that regional uptake of [18F]5 is sen-
sitive to FAAH activity.
(3) FAAH is inactivated by N-alkyl-O-arylcarbamates by car-
bamoylation of the Ser241 amino acid, resulting in ejection
of the O-aryl residue.43,44 Thus it was anticipated that intro-
duction of the radiolabel on the N-alkyl chain of 5 would
result in the irreversible tagging of FAAH with 18F upon
binding. To demonstrate this, excised rat brain was homog-
enized and repeatedly extracted with solvent to measure the
amount of radiolabel irreversibly bound to rat brain paren-
chyma following radiotracer injection (Fig. 3).37 Less than
10% of total radioactivity could be extracted, demonstrating
the irreversible nature of the binding. This irreversible bind-
ing was mediated by FAAH as demonstrated by its almost
complete abolishment by pre-treatment of animals with
URB597. Scheme 3 depicts the putative mechanism of action
of [18F]5.Figure 6. Correlation between regional brain uptake of FAAH radiotracers and
regional FAAH enzyme activity in rat brain. Data taken from this work ([18F]5
uptake); Wilson et al., ([11C]CURB and compound [11C]8 uptake);26,28 and Thomas
et al., (FAAH enzyme activity).16 Error bars represent standard deviation from the
mean.
Scheme 3. Putative mechanism of irreversible binding of [18F]5 to FAAH. Carbam-
oylation of the serine241 residue results in FAAH tagged with the [18F]ﬂuoropen-
tylcarbamoyl group.
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depicted by ex vivo autoradiography studies are in close
agreement with previous autoradiography, immunohisto-
chemical, and immunoreactivity studies which measured
the patterns of FAAH activity, mRNA, and expression in rat
brain, including high levels in the ventricles
(Fig. 5).16,39,41,45 Speciﬁcity of uptake was again demon-
strated by the complete disappearance of binding following
pretreatment with a selective FAAH inhibitor.
4. Conclusions
Wehave identiﬁed and characterized, in vitro and ex vivo in rats,
a novel 18F-labelled radiotracer for PET imaging of FAAH. [18F]5
shows high brain uptake upon intravenous administration with
binding which is sensitive to FAAH regional activity. As demon-
strated with dissection studies and ex vivo autoradiography, [18F]5
binds to FAAHwith a high degree of selectivity and speciﬁcity. These
properties suggest that the radiotracer is eminently suitable for neu-
roimaging of FAAH in the living human brain using PET. Clinical
studies with [18F]5 are being pursued in our laboratory.
5. Experimental methods
5.1. Chemistry
A Scanditronix MC 17 cyclotron was used for radionuclide pro-
duction. Puriﬁcations and analyses of radioactive mixtures were
performedbyhighperformance liquid chromatography (HPLC)with
an in-line UV (254 nm) detector in series with a NaI crystal radioac-
tivity detector (puriﬁcations) or a Bioscan Flowcount coincidence
radioactivitydetector (analyses). Isolated radiochemical yieldswere
determined with a dose-calibrator (Capintec CRC-712M). Unless
stated otherwise, all radioactivity measurements were normalised
for radioactive decay. Proton and carbon-13 NMR spectra were re-
corded at 25 ConaVarianMercury400 MHz spectrometer. Electro-
spray ionization mass spectrometry was conducted withMDS Sciex
QStarmass spectrometer to obtain the HRMS. All tested compounds
had a purity of >95% as determined by reverse-phase HPLC. All ani-
mal experiments were carried out under humane conditions, with
approval from the Animal Care Committee at the Centre for Addic-
tion and Mental Health, and in accordance with the guidelines set
forth by the Canadian Council on Animal Care. Rats (male, Spra-
gue–Dawley, 300–350 g) were kept on a reversed 12-h light/12-h
dark cycle and allowed food and water ad libitum.
5.2. tert-Butyl (5-hydroxypentyl)carbamate (1)
A mixture of 5-amino-1-pentanol (3.0 g, 29.1 mmol), t-Boc
anhydride (6.1 g, 34.9 mmol), and K2CO3 (4 g) in 50/50 water/methanol (25 mL) was stirred at ambient temperature for 2 h.
The reaction mixture was quenched with water (25 mL) and ex-
tracted with EtOAc (2  25 mL). Combined extracts were washed
with water and brine, dried (MgSO4), and ﬁltered. Solvent removal
gave the product as a viscous colourless oil (4.4 g, 74%). 1H NMR
(CDCl3): d ppm 1.3–1.63 (m, 15H) 3.07–3.18 (m, 2H) 3.65 (t,
J = 6.44 Hz, 2H) 4.55 (br s, 1H). 13C NMR (CDCl3): d ppm 22.89,
28.38, 29.80, 32.20, 40.39, 62.53. 79.07, 156.08. HRMS (ESI+) m/z
calcd for [M+H]+ C10H22NO3 204.15997, found 204.16070.
5.3. 5-((tert-Butoxycarbonyl)amino)pentyl 4-
methylbenzenesulfonate (2)
A mixture of tert-butyl (5-hydroxypentyl)carbamate (1.5 g,
7.4 mmol), p-toluenesulfonyl chloride (1.5 g, 7.9 mmol), triethylamine
(100 lL, 0.72 mmol), and potassium carbonate (2 g, 14.5 mmol) in
dichloromethane (10 mL) was stirred at ambient temperature for
3 days. Water (100 mL) was added and the mixture extracted with
ethyl acetate (2 50mL). Thecombinedorganicextractswerewashed
withbrine, dried (Na2SO4), ﬁlteredand solvent removed to leavea light
brown oil (2.41 g). Flash chromatography (hexane/EtOAc, 30:70) gave
a colourless oil fromheart fractionswhich crystallisedupon trituration
withpentane togive theproductasawhite solid (0.97 g,37%).A further
1.2 g (45%) was isolated from other fractions. Mp 47–48 C. 1H NMR
(CDCl3): d ppm 1.30–1.38 (m, 2H) 1.40–1.48 (m, 11H) 1.61–1.71 (m,
2H) 2.45 (s, 3H) 3.06 (q, J = 6.56 Hz, 2H) 4.02 (t, J = 6.33 Hz, 2H) 4.50
(br s, 1H) 7.35 (m, J = 7.99 Hz, 2H) 7.79 (m, 2H). 13C NMR (CDCl3): d
ppm 21.85, 22.88, 28.62, 29.65, 40.44, 70.55, 79.36, 128.10, 130.05,
133.35, 144.94, 156.14. HRMS (ESI+)m/z calcd for [M+H]+ C17H28NO5S
358.1683, found 358.1679.
5.4. tert-Butyl (5-ﬂuoropentyl)carbamate (3)
To a stirred solutionofDAST (1.87 ml, 19 mmol) inDCM(5 mL) at
70 C was added a solution of tert-butyl (5-hydroxypentyl) carba-
mate (3 g, 14 mmol) in DCM (6 mL) over 30 min. The mixture was
stirred for 12 h at room temperature, quenchedwith saturatedNaH-
CO3 (25 mL) and theorganic layer separated. The aqueousphasewas
extracted with DCM (10 mL) and the combined organic extracts
dried (MgSO4), ﬁltered, and volatiles evaporated. The product was
obtained as a colourless oil upon puriﬁcation by silica column chro-
matography with DCM/hexane 1/1 as mobile phase. (1.3 g, 43%) 1H
NMR (CDCl3): d ppm 1.39–1.57 (m, 13H) 1.62–1.78 (m, 2H) 3.12
(q, J = 6.24 Hz, 2H), 4.43 (dt, J = 47.9 Hz, 6.05 Hz, 2H). 13C NMR
(CDCl3): d ppm 22.47 (d, J = 5.37 Hz) 28.37, 29.67, 30.00 (d,
J = 19.94 Hz), 40.35, 79.03, 83.87 (d, J = 164.09 Hz,) 155.96. 19F
NMR (CDCl3) d ppm) 47.59 (tt, J = 47.30, 25.94 Hz). HRMS (ESI+) m/
z calcd for [M+H]+ C10H21FNO2 206.15563, found 206.15582.
5.5. 5-Fluoropentylamine hydrochloride (4)
AsolutionofHCl inMeOH(3 M,6 mL)was slowlyadded to a solu-
tion of tert-butyl (5-ﬂuoropentyl)carbamate (0.100 g, 0.49 mmol) in
CHCl3 (5 mL) at room temperature. After 12 h, volatiles were evapo-
rated to give 5-ﬂuoropentylamine hydrochloride (0.065 g, 94%) as a
light brownhygroscopic solid. 1HNMR (MeOH-d4): dppm1.43–1.58
(m, 2H), 1.65–1.84 (m, 4H), 2.95 (t, J = 7.61 Hz, 2H), 4.45 (dt, J = 6.05,
47 .4 Hz, 2H) 4.51. 13C NMR (MeOH-d4): d ppm22.02 (d, J = 5.37 Hz),
26.75, 29.56 (d, J = 19.94 Hz), 39.27, 83.18 (d, J = 164.09 Hz) 19FNMR
(MeOH-d4) d ppm) 45.69 (m). HRMS (ESI+) m/z calcd for [M+H]+
C5H13F 106.10320, found 106.10296.
5.6. 3-(4,5-Dihydrooxazol-2-yl)phenyl (5-ﬂuoropentyl)
carbamate (5)
A solution of 5-ﬂuoropentylamine hydrochloride (95 mg,
0.67 mmol) in CH3CN/H2O (4:1, 5 mL) was added to a stirred mix-
4356 O. Sadovski et al. / Bioorg. Med. Chem. 21 (2013) 4351–4357ture of 3-(4,5-dihydrooxazol-2-yl)phenyl (4-nitrophenyl) carbon-
ate (170 mg, 0.52 mmol) and KHCO3 (200 mg, 2.0 mmol) in CH3CN
(5 mL). The mixture was stirred at room temperature for 3 h then
DCM (10 mL) and satd aqueous NaHCO3 (50 mL) were added. The
aqueous layer was extracted with DCM and the combined organic
layers ﬁltered and solvent removed to leave a light brown oil
(143 mg). Flash chromatography (hexane/EtOAc; 50:50) on silica
gel gave a colourless oil which upon trituration with 20 mL hexane
gave the desired product as a white solid (72 mg, 47% yield); mp
74.5–77 C. 1H NMR (CDCl3): d ppm 1.46–1.54 (m, 2H), 1.60–1.81
(m, 4H), 3.28 (q, J = 6.63 Hz, 2H), 4.05 (t, J = 9.56 Hz, 2H), 4.37–
4.46 (m, 3H), 4.52 (t, J = 5.85 Hz, 1H), 5.19 (br s, 1H), 7.23–7.29
(m, 1H), 7.39 (t, J = 8.00 Hz, 1H), 7.70 (s, 1H), 7.78 (d, J = 7.80 Hz,
1H). 13C NMR (CDCl3): d ppm 22.30 (d, J = 5.37 Hz), 29.27, 29.81
(d, J = 19.94 Hz), 40.89, 54.74, 67.53, 83.67 (d, J = 164.86 Hz),
121.30, 124.42, 124.82, 128.84, 129.05, 150.77, 154.15, 163.79.
19F NMR (CDCl3): d ppm 47.39 (m). HRMS (ESI+) m/z calcd for
[M+H]+ C15H20FN2O3 295.14580, found 295.14450.
5.7. 3-(4,5-Dihydrooxazol-2-yl)phenyl (4-nitrophenyl)
carbonate (6)
A solution of p-nitrophenylchloroformate (120 mg, 0.6 mmol) in
CH3CN (2mL) was added to a stirred solution of 3-(4,5-dihydrooxa-
zol-2-yl)phenol46 (100 mg, 0.6 mmol) andDIPEA (110 lL, 0.63 mmol))
in CH3CN (2mL) andDMSO (0.8 mL). Themixturewas stirred at ambi-
ent temperature for 20 min then quenchedwith 5% citric acid (17mL).
The resultant precipitate was collected by vacuum ﬁltration and
washedwithcopiousamountsofwater.Drying invacuogave theprod-
uct as a pale yellowpowderwhichwas puriﬁed by ﬂash chromatogra-
phy (hexane/EtOAc, 80:20 to 30:70) yielding a white solid (77mg,
39%); mp 150–152 C. 1H NMR (CDCl3): d ppm 4.10 (t, J = 9.65 Hz,
2H), 4.47 (t, J = 9.65 Hz, 2H), 7.38–7.43 (m, 1H), 7.47–7.53 (m, 3H),
7.88–7.93 (m, 2H), 8.30–8.36 (m, 2H). 13C NMR (CDCl3): d ppm 55.02,
67.90, 120.73, 121.74, 123.52, 125.43, 126.44, 129.69, 129.78, 145.69,
150.52, 150.87, 155.20, 163.45. HRMS (ESI+) m/z calcd for [M+H]+
C16H13N2O6 329.0768, found 329.0763.
5.8. Radiosynthesis of [18F]5
Procedures were initially carried out by hand using <1 MBq of
[18F]ﬂuoride to optimize reaction conditions. Subsequently the
radiosynthesis was carried out using a radiosynthesis module
(for details see47) using 14–20 GBq. [18F]Fluoride was produced
by the 18O(p, n)18F nuclear reaction using >95% enriched
[18O]H2O. The [18F]ﬂuoride was trapped on a Chromaﬁx ion-ex-
change 30-PS-HCO3 resin, and eluted into a glass reactor with a
solution consisting of 14.4 mg of 4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane (Kryptoﬁx 222,) and 3 mg of K2CO3
in 1 mL of 4% (v/v) water in acetonitrile.48 The solution was dried
by a combination of heat (90 C), vacuum, and N2 ﬂow (350 mL/
min) for 5 min. After cooling the reactor to 60 C, a solution of 2,
(5 mg. 14 lmol) in CH3CN (0.5 mL) was added with stirring and
heated to 80 C for 7 min. Then 2% aq H2SO4 (0.5 mL) was added,
heating and stirring continued for a further 7 min, and the solution
neutralized with phosphate buffer (0.5 mL, prepared by dissolving
K2HPO4 (34.84 g) and KOH (2.81 g) in water (250 mL)). A solution
of 6 (7 mg, 21.3 lmol) in 70% aq. CH3CN (1 mL) was added, with
heating at 80 C and stirring continued for a further 7 min. The
mixture was cooled to <45 C, quenched with water (2 mL), and
puriﬁed by HPLC using a Phenomenex Gemini C18 5 lm,
250  10 mm column with 35:65 CH3CN/H2O + 0.1 N ammonium
formate as eluent at 7 mL/min. The fraction containing [18F]5 was
collected, diluted with 25 mL of water, and trapped on a pre-con-
ditioned reverse-phase cartridge (Waters Sep-Pak tC18+). After
washing the cartridge with water (5 mL) to remove salts and resid-ual acetonitrile, it was eluted with ethanol (1 mL), chased with iso-
tonic citrate buffer (10 mL, pH 6), prepared by dissolving trisodium
citrate dehydrate (0.588 g) and disodium hydrogen citrate 1.5 hy-
drate (0.263 g) in water (100 mL), and passed through a sterile
0.2 lm ﬁlter into a sterile, pyrogen-free bottle. Co-injection of
the radioactive product with an authentic standard of 5 under sev-
eral reverse-phase conditions, varying solvents (methanol, acetoni-
trile, THF) pH, (7.0, 5.0, 4.0) with several analytical HPLC columns
(Waters, Grace, Phenomenex, ThermoScientiﬁc, C18 and C8) estab-
lished the identity of the radiotracer. Under all conditions [18F]5
co-chromatographed with authentic 5. The formulated radiotracer
displayed <5% radiolysis 120 min post formulation and proved to
be sterile and pyrogen-free, suitable for animal studies.
5.9. Log P measurements
Thepartition coefﬁcients of [18F]5, between1-octanol and0.02 M
phosphate buffer at pH 7.4, was determined to be 2.33 ± 0.01 by a
previously described method, replicated eight times.49
5.10. FAAH assays in vitro
FAAHactivitywas assayed in rat brain homogenates as described
previously.50 Brieﬂy, 5 (in ethanol) was added to homogenates of
frozen brains (minus cerebellum; 0.5 lg per assay) from adult rats
(Wistar or Sprague–Dawley) in 50 mM Tris–HCl buffer, pH 7.4 con-
taining 1 mM EDTA and 3 mMMgCl2 and preincubated at 37 C for
the times shown in Figure 1. [3H]Anandamide, labelled in the etha-
nolamine part of the molecule (American Radiolabeled Chemicals,
Inc., St. Louis, MO) in 10 mM Tris–HCl, 1 mM EDTA, pH 7.4, contain-
ing 1% w/v fatty acid-free bovine serum albumin was then added to
give a ﬁnal substrate concentration of 0.5 lM and assay volume of
200 ll. The assay tubeswere then incubated for 10 minat 37 Cafter
which reactionswere stoppedbyplacing the tubes on ice andadding
activated charcoal (80 + 320 ll 0.5 M HCl). After mixing and phase
separation, aliquots of the supernatants were analysed for tritium
content by liquid scintillation spectroscopywith quench correction.
Blanks contained assay buffer in place of enzyme homogenate.
5.11. Biodistribution studies in rats
Rats, in a restraining box, received 3–4MBqof high speciﬁc activity
[18F]5 (0.2–1 nmol/kg) in 0.3 mL of 10% ethanol in citrate buffer (pH 6)
via the tail vein which had been vasodilated in a warm water bath.
Groups of rats (n = 4–6)were sacriﬁcedbydecapitation at various time
intervals after radiotracer administration, thebrain surgically removed
from the skull and stored on ice. Brain regions were excised, blotted,
andweighedwhile bloodwas collected (from the trunk). Radioactivity
in tissueswasassayed inanautomatedgammacounter, backcorrected
to time of injection, using diluted aliquots of the initial injected dose as
standards. Values are reported as standard uptake values (SUVs,
mean ± standard deviation) deﬁned as % injected dose/g of tissue di-
vided by rat weight in kg. Treated groups were compared to those of
the vehicle-treated group by Student’s t test. Statistical comparisons
were considered signiﬁcant when p <0.05. For pharmacological chal-
lenge studies in rats, groups of rats (n = 4) were pre-treated with solu-
tions of the challenge drug (2 mL/kg in 5% Tween 80 in saline ip) or
vehicle 40 min prior to radiotracer injection. Animals were sacriﬁced
40 min post radiotracer administration and radioactivity in tissues
measured as describe above.
5.12. Irreversible binding of [18F]5 to FAAH and metabolite
studies
Following tail-vein injection of [18F]5 groups of 4–6 rats were
sacriﬁced at various timepoints and the whole brain was surgically
O. Sadovski et al. / Bioorg. Med. Chem. 21 (2013) 4351–4357 4357removed from the skull, washed in saline, and kept on ice. Rats in
one group were pretreated with URB597 (2 mg/kg, 2 mL/kg in sal-
ine with 5% Tween80, ip) 1 h prior to radiotracer injection to mea-
sure speciﬁc binding. Brains were then homogenized (Polytron,
setting 7) in 5 mL of cold 80% acetonitrile/20% aqueous hydrochlo-
ric acid (0.01%) and centrifuged (17,000 rpm, 10 min). Following
careful decantation of the supernatants, the pellets were resus-
pended in extraction solvent (5 mL) and centrifuged again. After
repeating the extraction procedure once more, aliquots from the
combined supernatants from each rat was removed, weighed and
counted for radioactivity. Pellets were also counted for radioactiv-
ity. For metabolism studies blood was collected from the trunk in a
heparinised tube and centrifuged to separate the plasma, which
was treated with 10% by volume of acetic acid. Plasma and extracts
of homogenized brain were directly analysed by HPLC analysis
using minor modiﬁcations of the method described by Hilton.26,51
5.13. Autoradiography experiments
Male Sprague–Dawley rats with body weights ranging from 310
to 330 g were injected in the tail vein with [18F]5 (45–55 MBq, 0.7–
0.8 nmol/kg). Forty minutes prior to the radiotracer injection, some
of the animals were pretreated with vehicle (5% Tween80 in sal-
ine) or PF-04457845 (0.5 mg/kg, ip). All rats were sacriﬁced 40 min
after the radiotracer injection. Brains were rapidly removed, frozen
over dry ice, sliced into coronal 20-lm sections at 20 C, and
thaw-mounted onto Fisher Superfrost slides. Slides were quickly
dried on a slide warmer and then exposed to Kodak Biomax ﬁlm
for 6 days. The average time between sacriﬁce and beginning of
ﬁlm exposure was 70 min.
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